Physician profile
Devak G Desai
NPI 1164677613
$1,161.25
in general payments reported to CMS, 2019-2025
9 companies · $185 in 2025
The $185 reported for 2025 was less than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $268 · 2020: $39.78 · 2021: $125 · 2022: $42.32 · 2023: $259 · 2024: $242 · 2025: $185.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $686.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $686.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $360.74 | 2021-2024 | Nuzyra |
| Gilead Sciences, INC. | $259.40 | 2023-2025 | Biktarvy |
| Insmed, INC. | $150.45 | 2019-2020 | |
| Melinta Therapeutics, LLC | $133.71 | 2019 | |
| Shionogi INC | $121.84 | 2024 | Fetroja |
| Abbvie INC. | $61.27 | 2022-2023 | Teflaro |
| Viiv Healthcare Company | $28.84 | 2025 | Cabenuva |
| Janssen Pharmaceuticals, INC | $23.54 | 2020 | |
| Beigene USA, INC. | $21.46 | 2025 | Tevimbra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devak Desai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.